<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: depend on", fill: "#fcc200"},
{source: "2: depend on", target: "2: severity length", fill: "#fcc200"},
{source: "2: severity length", target: "2: new product approvals", fill: "#fcc200"},
{source: "2: new product approvals", target: "2: introductions by", fill: "#fcc200"},
{source: "2: introductions by", target: "2: competitors", fill: "#fcc200"},
{source: "2: competitors", target: "2: competition", fill: "#fcc200"},
{source: "2: competition", target: "2: development", fill: "#fcc200"},
{source: "2: development", target: "2: investments", fill: "#fcc200"},
{source: "2: investments", target: "2: inventories", fill: "#fcc200"},
{source: "2: inventories", target: "2: retailer promotional", fill: "#fcc200"},
{source: "2: depend on", target: "4: Accordingly the Company ", fill: "#ace5ee"},
{source: "4: Accordingly the Company ", target: "4: significant", fill: "#ace5ee"},
{source: "4: Accordingly the Company ", target: "6: operations depend", fill: "#c19a6b"},
{source: "6: operations depend", target: "6: significant degree upon", fill: "#c19a6b"},
{source: "6: significant degree upon", target: "6: API The Company ", fill: "#c19a6b"},
{source: "6: API The Company ", target: "6: prescription products", fill: "#c19a6b"},
{source: "6: prescription products", target: "6: bioequivalent", fill: "#c19a6b"},
{source: "6: bioequivalent", target: "6: branded counterparts which", fill: "#c19a6b"},
{source: "6: branded counterparts which", target: "6: bioequivalency studies", fill: "#c19a6b"},
{source: "6: bioequivalency studies", target: "6: expensive clinical trials", fill: "#c19a6b"},
{source: "6: expensive clinical trials", target: "6: topical products", fill: "#c19a6b"},
{source: "6: operations depend", target: "15: Therefore ", fill: "#51484f"},
{source: "15: Therefore ", target: "15: new product introductions", fill: "#51484f"},
{source: "15: new product introductions", target: "15: introductions", fill: "#51484f"},
{source: "15: introductions", target: "15: necessary", fill: "#51484f"},
{source: "15: necessary", target: "15: current financial condition", fill: "#51484f"},
{source: "15: current financial condition", target: "15: previously marketed by", fill: "#51484f"},
{source: "15: previously marketed by", target: "15: opportunities", fill: "#51484f"},
{source: "15: opportunities", target: "15: financial growth", fill: "#51484f"},
{source: "15: Therefore ", target: "16: investment", fill: "#b87333"},
{source: "16: investment", target: "16: development", fill: "#b87333"},
{source: "16: development", target: "16: historical levels due", fill: "#b87333"},
{source: "16: historical levels due", target: "16: ongoing expansion into", fill: "#b87333"},
{source: "16: ongoing expansion into", target: "16: manufacture", fill: "#b87333"},
{source: "16: manufacture", target: "16: generic prescription drugs as well as", fill: "#b87333"},
{source: "16: generic prescription drugs as well as", target: "16: qualified manufacturer", fill: "#b87333"},
{source: "16: qualified manufacturer", target: "16: new products", fill: "#b87333"},
{source: "16: new products", target: "16: switching from prescription", fill: "#b87333"},
{source: "16: investment", target: "18: Should the Company ", fill: "#006b3c"},
{source: "18: Should the Company ", target: "18: attract qualified", fill: "#006b3c"},
{source: "18: attract qualified", target: "18: longterm sales growth", fill: "#006b3c"},
{source: "18: longterm sales growth", target: "18: profit would", fill: "#006b3c"},
{source: "18: profit would", target: "18: adversely impacted", fill: "#006b3c"},
{source: "18: Should the Company ", target: "19: operations", fill: "#74c365"},
{source: "19: operations", target: "19: concentrated", fill: "#74c365"},
{source: "19: operations", target: "21: The Company ", fill: "#fc0"},
{source: "21: The Company ", target: "21: concentrated manufacturing facilities", fill: "#fc0"},
{source: "21: The Company ", target: "22: significant disruption", fill: "#ddadaf"},
{source: "22: significant disruption", target: "22: fire tornado storm", fill: "#ddadaf"},
{source: "22: fire tornado storm", target: "22: pandemic at", fill: "#ddadaf"},
{source: "22: pandemic at", target: "22: facilities could impair", fill: "#ddadaf"},
{source: "22: facilities could impair", target: "22: andor ship products on", fill: "#ddadaf"},
{source: "22: andor ship products on", target: "22: timely basis which could", fill: "#ddadaf"},
{source: "22: timely basis which could", target: "22: financial position", fill: "#ddadaf"},
{source: "22: significant disruption", target: "41: opportunities", fill: "#50c878"},
{source: "41: opportunities", target: "41: Company ", fill: "#50c878"},
{source: "41: Company ", target: "41: significant store", fill: "#50c878"},
{source: "41: significant store", target: "41: analgesic products will", fill: "#50c878"},
{source: "41: analgesic products will", target: "41: driven by", fill: "#50c878"},
{source: "41: driven by", target: "41: offer new products", fill: "#50c878"},
{source: "41: offer new products", target: "41: existing domestic customers", fill: "#50c878"},
{source: "41: opportunities", target: "START_HERE", fill: "#50c878"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Collaborate</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Protest demonstrations</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_Development_Index">Human Development Index</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_services">Financial services</a></td>
      <td>Financial services are the economic services provided by  the finance industry, which encompasses a broad range of businesses that manage money, including credit unions, banks, credit-card companies, insurance companies, accountancy companies, consumer-finance companies, stock brokerages, investment funds, individual asset managers, and some government-sponsored enterprises.\n\n\n== History ==\n\nThe term "financial services" became more prevalent in the United States partly as a result of the Gramm–Leach–Bliley Act of the late 1990s, which enabled different types of companies operating in the U.S. financial services industry at that time to merge.Companies usually have two distinct approaches to this new type of business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Weather_Company">The Weather Company</a></td>
      <td>The Weather Company is a weather forecasting and information technology company that owns and operates weather.com and Weather Underground. The Weather Company has been a subsidiary of the Watson &amp; Cloud Platform business unit of IBM since 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_position_of_the_United_States">Financial position of the United States</a></td>
      <td>The financial position of the United States includes assets of at least $269.6 trillion (1576% of GDP) and debts of $145.8 trillion (852% of GDP) to produce a net worth of at least $123.8 trillion (723% of GDP) as of Q1 2014.\nThe U.S. increased the ratio of public and private debt from 152% GDP in 1980 to peak at 296% GDP in 2008, before falling to 279% GDP by Q2 2011.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Futures_contract">Futures contract</a></td>
      <td>In finance, a futures contract (sometimes called a futures) is a standardized legal contract to buy or sell something at a predetermined price for delivery at a specified time in the future, between parties not yet known to each other. The asset transacted is usually a commodity or financial instrument.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_Financial_Reporting_Standards">International Financial Reporting Standards</a></td>
      <td>International Financial Reporting Standards, commonly called IFRS, are accounting standards issued by the IFRS Foundation and the International Accounting Standards Board (IASB). They constitute a standardised way of describing the company's financial performance and position so that company financial statements are understandable and comparable across international boundaries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reliance_Retail">Reliance Retail</a></td>
      <td>Reliance Retail is an Indian retail company and a subsidiary of Reliance Industries Limited. Founded in 2006, it is the largest retailer in India in terms of revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Subsidiary">Subsidiary</a></td>
      <td>A subsidiary, subsidiary company or daughter company is a company owned or controlled by another company, which is called the parent company or holding company. Two or more subsidiaries that belong to the same parent company are called sister companies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PERRIGO CO     Item 1A  <font color="blue">Risk Factors</font>                                                                                                           18  Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Fluctuation in Quarterly Results    The Companyapstas quarterly operating results <font color="blue">depend on</font> a variety of factors  including, but not limited to, the severity, length and timing of the  cough/cold/flu season, the timing of <font color="blue">new product approvals</font> and <font color="blue"><font color="blue">introduction</font>s by</font>  <font color="blue">the Company </font>and its <font color="blue">competitors</font>, price <font color="blue">competition</font>, the magnitude and timing of  research and <font color="blue">development</font> <font color="blue"><font color="blue">investment</font>s</font>, changes in the levels of <font color="blue">inventories</font>  maintained by the Companyapstas customers and the timing of <font color="blue">retailer promotional</font>  programs</td>
    </tr>
    <tr>
      <td><font color="blue">Restrictions </font>on the sale of <font color="blue"><font color="blue">pseudoephedrine</font> containing products</font> are  likely to have an <font color="blue"><font color="blue">adverse <font color="blue">impact on</font></font> sales</font> of the Companyapstas cough/cold/flu and  <font color="blue">allergy products</font> in fiscal 2007, which may affect the <font color="blue">typical seasonal sales</font>  patterns of these products</td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">the Company </font>may be subject to  <font color="blue">significant</font> and unanticipated quarter-to-quarter <font color="blue">fluctuation</font>s</td>
    </tr>
    <tr>
      <td>Potential Volatility of Stock Price    The market price of the Companyapstas <font color="blue">common stock</font> has been, and could be, subject  to <font color="blue">wide <font color="blue">fluctuation</font>s</font> in response to, among other things, quarterly <font color="blue">fluctuation</font>s  in operating results, <font color="blue">adverse <font color="blue">circumstances</font> affecting</font> the <font color="blue">introduction</font> or market  <font color="blue">acceptance</font> of <font color="blue">new products</font>, failure to <font color="blue">meet published</font> estimates of or changes in  earnings estimates by securities analysts, announcements of <font color="blue">new products</font> or  enhancements by <font color="blue">competitors</font>, receipt of <font color="blue">regulatory</font> approvals by <font color="blue">competitors</font>,  sales of <font color="blue">common stock</font> by existing holders, loss of key personnel, market  <font color="blue">conditions</font> in the industry, shortages of <font color="blue">key product inventory components</font> and  general economic <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Commercialization of New Products / Research and Development    The Companyapstas future results of <font color="blue"><font color="blue">operations</font> depend</font>, to a <font color="blue">significant</font> degree, upon  its ability to <font color="blue">successfully</font> commercialize <font color="blue">additional</font> generic drugs and/or  innovative <font color="blue">pharmaceutical</font>s and <font color="blue">API <font color="blue">The Company </font></font>must develop, test and  <font color="blue">manufacture</font> generic <font color="blue"><font color="blue">prescription</font> products</font> as well as prove that its generic  <font color="blue"><font color="blue">prescription</font> products</font> are the <font color="blue">bioequivalent</font> of their branded counterparts, which  requires <font color="blue">bioequivalency studies</font> or even more <font color="blue">expensive clinical trials</font> in the  case of <font color="blue">topical products</font></td>
    </tr>
    <tr>
      <td>OTC drugs may require <font color="blue">bioequivalency studies</font> as well</td>
    </tr>
    <tr>
      <td>All <font color="blue">major products must meet <font color="blue">regulatory</font> standards</font> and receive <font color="blue">regulatory</font>  approvals</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and commercialization process, particularly with  respect to <font color="blue">innovative products</font>, is both time consuming and costly and involves a  high degree of business risk</td>
    </tr>
    <tr>
      <td>Products currently under <font color="blue">development</font>, if and when  fully developed and tested, may not perform as expected, <font color="blue">necessary</font> <font color="blue">regulatory</font>  <font color="blue">approvals may</font> not be obtained in a <font color="blue">timely manner</font>, if at all, and <font color="blue">the Company </font>may  not be able to <font color="blue">successfully</font> and profitably produce and <font color="blue">market <font color="blue">such product</font>s</font></td>
    </tr>
    <tr>
      <td>Delays in any part of the process or the Companyapstas <font color="blue">inability</font> to obtain  <font color="blue">regulatory</font> approval of its products (including products developed by others to  which <font color="blue">the Company </font>has exclusive marketing rights) could <font color="blue">adversely</font> affect  operating results <font color="blue">by restricting</font> or delaying its <font color="blue">introduction</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Even upon the successful <font color="blue">development</font> of a product, the Companyapstas customerapstas  failure to launch a <font color="blue">product could <font color="blue">adversely</font> affect</font> operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Continuous  </font><font color="blue">introduction</font>s of <font color="blue">new products</font> and <font color="blue">product categories</font> are critical to the  Companyapstas business</td>
    </tr>
    <tr>
      <td>Product <font color="blue">margins may decline over</font> time                                         - 18 -  <PAGE>    due to the productapstas aging life cycle, changes in <font color="blue">consumer choice</font> or  <font color="blue">development</font>s in <font color="blue">drug delivery technology</font></td>
    </tr>
    <tr>
      <td>Therefore, new product <font color="blue">introduction</font>s  are <font color="blue">necessary</font> for maintenance of the Companyapstas <font color="blue">current <font color="blue">financial condition</font></font> and  <font color="blue">introduction</font>s of products not <font color="blue">previously marketed by</font> <font color="blue">the Company </font>provide  <font color="blue">opportunities</font> for <font color="blue">financial growth</font></td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">investment</font> in research and <font color="blue">development</font> is expected to be at or  above <font color="blue">historical levels due</font> to the Companyapstas <font color="blue">ongoing expansion into</font> the  <font color="blue">manufacture</font> and sale of <font color="blue">generic <font color="blue">prescription</font> drugs as well as</font> the high cost of  developing and becoming a qualified <font color="blue">manufacture</font>r of <font color="blue">new products</font> that are  <font color="blue">switching from <font color="blue">prescription</font></font> to OTC status</td>
    </tr>
    <tr>
      <td>The ability to <font color="blue">attract <font color="blue">scientists</font></font>  proficient in emerging delivery forms and/or contracting with a <font color="blue">third party</font>  innovator in order to generate <font color="blue">new products</font> of this type is a critical element  of the Companyapstas long-term plans</td>
    </tr>
    <tr>
      <td><font color="blue">Should <font color="blue">the Company </font></font>fail to <font color="blue">attract qualified</font>  employees or enter into reasonable agreements with <font color="blue">third party</font> innovators,  long-term <font color="blue">sales growth</font> and <font color="blue">profit would</font> be <font color="blue"><font color="blue">adversely</font> impacted</font></td>
    </tr>
    <tr>
      <td>Manufacturing Facilities    The Companyapstas US <font color="blue">operations</font> are <font color="blue">concentrated</font> in Allegan, Michigan; Greenville,  South Carolina and the Bronx, New York</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>65prca of the Companyapstas  revenues are related to these <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has  <font color="blue">concentrated</font> <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> in Israel which comprise <font color="blue">approximately</font> 13prca  of the Companyapstas revenues</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> <font color="blue">disruption</font> resulting from, but not  limited to, fire, tornado, storm, material supply, insufficient quality, or flu  <font color="blue">pandemic at</font> any of the Companyapstas <font color="blue"><font color="blue">facilities</font> could impair</font> its ability to develop,  produce and/or ship products on a timely basis, which could have a material  adverse effect on the Companyapstas business, <font color="blue">financial position</font> and operating  results</td>
    </tr>
    <tr>
      <td>Regulatory Environment    Several US and foreign agencies regulate the <font color="blue">manufacturing</font>, processing,  <font color="blue">formulation</font>, packaging, labeling, testing, storing, <font color="blue">distribution</font>, <font color="blue">advertising</font>  and sale of the Companyapstas products</td>
    </tr>
    <tr>
      <td>Various state and <font color="blue">local agencies also</font>  regulate these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font><font color="blue">manufacture</font>s and markets  certain of its products in <font color="blue">accordance with</font> the <font color="blue">guidelines established by</font>  voluntary standard <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Should <font color="blue">the Company </font></font>fail to <font color="blue"><font color="blue">adequately</font> conform</font>  to these <font color="blue">regulations</font> and guidelines, there may be a <font color="blue">significant</font> adverse impact  on the operating results of the Company</td>
    </tr>
    <tr>
      <td>In particular, packaging or labeling  changes <font color="blue">mandated by</font> the FDA can have a material <font color="blue">adverse <font color="blue">impact on</font></font> the results of  <font color="blue">operations</font> of the Company</td>
    </tr>
    <tr>
      <td>Required changes could be related to safety or  <font color="blue"><font color="blue">effective</font>ness issues</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that it has a good <font color="blue"><font color="blue">relationship</font> with</font>  the FDA, which it intends to maintain</td>
    </tr>
    <tr>
      <td>If these <font color="blue"><font color="blue">relationship</font>s should</font>  deteriorate, however, the Companyapstas ability to <font color="blue">bring new</font> and <font color="blue">current products</font> to  <font color="blue">market could</font> be impeded</td>
    </tr>
    <tr>
      <td>In addition, the FDAapstas policy regarding the award of a 180-day market  <font color="blue">exclusivity</font> period to generic <font color="blue">manufacture</font>rs who <font color="blue">successfully</font> challenge patents  relating to <font color="blue">specific products continues</font> to be the subject of extensive  <font color="blue">litigation</font> in the US The FDAapstas <font color="blue">current interpretation</font> of Hatch-Waxman is to  award 180 days of <font color="blue">exclusivity</font> to the first generic <font color="blue">manufacture</font>r who files a  <font color="blue">successful paragraph</font> IV <font color="blue">certification under</font> Hatch-Waxman <font color="blue">challenging</font> the patent  of the branded product, regardless of whether the <font color="blue">manufacture</font>r was sued for  <font color="blue">patent <font color="blue">infringement</font></font></td>
    </tr>
    <tr>
      <td>Although the FDAapstas interpretation may benefit some of the  products in the Companyapstas pipeline, it <font color="blue">may <font color="blue">adversely</font> affect others</font></td>
    </tr>
    <tr>
      <td>The Medicare  Prescription Drug Improvement and Modernization Act of 2003 provides that the  180-day market <font color="blue">exclusivity</font> period provided under Hatch-Waxman is <font color="blue">triggered by</font>  the <font color="blue">commercial marketing</font> of the product</td>
    </tr>
    <tr>
      <td>However, the Medicare Prescription Drug  Act <font color="blue">also contains forfeiture provisions which</font>, if met, will deprive the first  paragraph IV filer of <font color="blue">exclusivity</font></td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">manufacture</font>r of the branded  <font color="blue">product may launch</font> a <font color="blue">generic version</font> of its own drug, known as an authorized  generic</td>
    </tr>
    <tr>
      <td>Under <font color="blue">certain <font color="blue">circumstances</font></font>, <font color="blue">the Company </font>may not be able to fully  exploit its 180-day <font color="blue">exclusivity</font> period resulting from it being the <font color="blue">first filer</font></td>
    </tr>
    <tr>
      <td>Store Brand Product Growth    The <font color="blue">future growth</font> of <font color="blue">domestic store</font> brand <font color="blue">products will</font> be <font color="blue">influenced by general</font>  economic <font color="blue">conditions</font>, which can <font color="blue">influence consumers</font> to switch to store brand  products, consumer perception and <font color="blue">acceptance</font> of the quality of the                                          -19-  <PAGE>    <font color="blue">products available</font>, the <font color="blue">development</font> of <font color="blue">new products</font> and/or product delivery  forms, the market <font color="blue">exclusivity</font> periods awarded on <font color="blue">prescription</font> to OTC switch  products and the Companyapstas ability to grow its store brand market share</td>
    </tr>
    <tr>
      <td>The  Company does not advertise like the national brand companies and thus is  dependent on <font color="blue">retailer promotional</font> spending to <font color="blue">drive sales volume</font> and increase  market share</td>
    </tr>
    <tr>
      <td>Growth <font color="blue">opportunities</font> for the products in which the <font color="blue">Company  </font>currently has a <font color="blue">significant</font> store brand market share (cough/cold/flu and  analgesic products) will be <font color="blue">driven by</font> the ability to offer <font color="blue">new products</font> to  <font color="blue">existing domestic customers</font></td>
    </tr>
    <tr>
      <td>Branded <font color="blue"><font color="blue"><font color="blue">pharmaceutical</font> companies</font> may use</font> state and  federal <font color="blue">regulatory</font> and <font color="blue">legislative</font> means to limit the use of brand equivalent  products</td>
    </tr>
    <tr>
      <td>Should store brand growth be limited by any of these factors, there  could be a <font color="blue">significant</font> <font color="blue">adverse <font color="blue">impact on</font></font> the operating results of the Company</td>
    </tr>
    <tr>
      <td>Competitive Issues    The markets for OTC <font color="blue">pharmaceutical</font>, <font color="blue">generic <font color="blue">pharmaceutical</font></font>, API and nutritional  products are highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is <font color="blue">based primarily on price</font>,  quality and <font color="blue">assortment</font> of products, <font color="blue">customer service</font>, marketing support and  <font color="blue">availability</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font><font color="blue">also comes from national</font> brand  companies and brand <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>That <font color="blue">competition</font> could be  <font color="blue">intensified should</font> those <font color="blue">companies lower prices</font> or <font color="blue">manufacture</font> their own store  brand or <font color="blue">generic <font color="blue">equivalent product</font>s</font></td>
    </tr>
    <tr>
      <td>Due to the high degree of price  <font color="blue">competition</font>, <font color="blue">the Company </font>has not <font color="blue">always been able</font> to <font color="blue">fully pass on cost</font>  increases to its customers</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to <font color="blue">pass on future cost increases</font>, the  impact of store brand <font color="blue">competitors</font> and the impact of national brand companies  <font color="blue">lowering prices</font> of their products or operating in the store brand <font color="blue">market could</font>  have a material <font color="blue">adverse <font color="blue">impact on</font></font> financial results</td>
    </tr>
    <tr>
      <td>In addition, since the  Company sells its nutritional <font color="blue">products through</font> retail drug, supermarket and mass  <font color="blue">merchandise chains</font>, it may experience increased <font color="blue">competition</font> in its nutritional  products business through <font color="blue">alternative</font> channels such as health food stores,  <font color="blue">direct mail</font> and <font color="blue">direct sales as</font> more consumers obtain <font color="blue">products through</font> these  channels</td>
    </tr>
    <tr>
      <td>Retailer <font color="blue">reverse auctions</font> have added a <font color="blue">new dimension</font> to <font color="blue">competition</font> as  some retailers have instituted this process to obtain <font color="blue">competitive</font> price quotes  over the world-wide web</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has evaluated, and <font color="blue">will continue</font> to  evaluate, the products and <font color="blue">product categories</font> in which it does business</td>
    </tr>
    <tr>
      <td>Future  <font color="blue">product line extensions</font>, or deletions, could have a material <font color="blue">impact on</font> the  Companyapstas <font color="blue">financial position</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Selling prices of generic drugs typically decline, sometimes dramatically, as  <font color="blue"><font color="blue">additional</font> companies</font> receive approvals for a given product, brands launch  <font color="blue">authorized generics</font> and <font color="blue">competition</font> intensifies</td>
    </tr>
    <tr>
      <td>To the extent that the <font color="blue">Company  </font>succeeds in being the first to market a <font color="blue">generic version</font> of a <font color="blue">significant</font>  product, the Companyapstas sales and profit can be <font color="blue">substantially increased</font> in the  <font color="blue">period following</font> the <font color="blue">introduction</font> of <font color="blue">such product</font> and prior to a competitorapstas  <font color="blue">introduction</font> of the <font color="blue">equivalent product</font></td>
    </tr>
    <tr>
      <td>The Companyapstas ability to sustain its  sales and <font color="blue"><font color="blue">profitability</font> on</font> any <font color="blue">product over</font> time is <font color="blue">dependent on both</font> the number  of new <font color="blue">competitors</font> for <font color="blue">such product</font>, some of whom may be <font color="blue">significant</font>ly larger  than the Company, and the timing of their approvals</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">competitors</font> are choosing to <font color="blue">consolidate</font> in the <font color="blue">generic <font color="blue">pharmaceutical</font></font>  industry</td>
    </tr>
    <tr>
      <td>This <font color="blue">consolidation may</font> create <font color="blue">larger companies with which</font> the <font color="blue">Company  </font><font color="blue">must compete</font> and <font color="blue">provide further pressure</font> to prices, <font color="blue">development</font> <font color="blue">activities</font> or  <font color="blue">customer retention</font></td>
    </tr>
    <tr>
      <td>The impact of <font color="blue">future consolidation</font> in the <font color="blue">industry could</font>  have a material <font color="blue">impact on</font> the Companyapstas <font color="blue">financial position</font> or results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, the Companyapstas API business is subject to increased <font color="blue">competition</font> from  other <font color="blue">manufacture</font>rs of API located in developing <font color="blue">countries such as</font> India and  Europe</td>
    </tr>
    <tr>
      <td>Such <font color="blue">competition</font> may result in loss of API customers and/or decreased  <font color="blue">profitability</font> in this business segment</td>
    </tr>
    <tr>
      <td>-20-  <PAGE>  Customer Issues    The Companyapstas <font color="blue">largest customer</font>, Wal-Mart, currently comprises <font color="blue">approximately</font> 22prca  of <font color="blue">total net sales</font></td>
    </tr>
    <tr>
      <td>Should Wal-Martapstas current <font color="blue"><font color="blue">relationship</font> with</font> the <font color="blue">Company  </font>change <font color="blue">adversely</font>, the resulting loss of business could have a material adverse  <font color="blue">impact on</font> the Companyapstas <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In  addition, while no other <font color="blue">customer individually comprises</font> more than 10prca of total  net sales, <font color="blue">the Company </font>does have other <font color="blue">significant</font> customers which, if the  <font color="blue">relationship</font> changes <font color="blue">significant</font>ly, could have a material <font color="blue">adverse <font color="blue">impact on</font></font> the  Companyapstas <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Maintaining </font>the supply <font color="blue">relationship</font>s with the Companyapstas customers is critical to  its success</td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Company </font></font>is unable to deliver to expected <font color="blue">customer service</font>  levels, customers may choose to <font color="blue">assess penalties</font>, obtain <font color="blue">alternate sources</font> for  products, withhold new product <font color="blue">introduction</font>s and/or end the <font color="blue"><font color="blue">relationship</font> with</font>  the Company</td>
    </tr>
    <tr>
      <td><font color="blue">Customers </font>may limit the level of <font color="blue">product sourcing with</font> the <font color="blue">Company  </font>in protection of the customerapstas own interests</td>
    </tr>
    <tr>
      <td>Any or all of these factors could  have a material <font color="blue">adverse <font color="blue">impact on</font></font> the Companyapstas <font color="blue">financial position</font> and results  of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The impact of <font color="blue">retailer consolidation could</font> have an <font color="blue">adverse <font color="blue">impact on</font></font> future  <font color="blue">sales growth</font></td>
    </tr>
    <tr>
      <td>If a large customer should encounter financial <font color="blue">difficulties</font>, the  exposure on <font color="blue">uncollectible</font> <font color="blue">receivables</font> and unusable inventory could have a  material <font color="blue">adverse <font color="blue">impact on</font></font> the Companyapstas <font color="blue">financial position</font> or results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on Personnel    The Companyapstas <font color="blue">future success will depend</font> in large part upon its ability to  attract and retain <font color="blue">highly skilled employees</font></td>
    </tr>
    <tr>
      <td>Key functions for the <font color="blue">Company  </font>include executive managers, operational managers, research and <font color="blue">development</font>  <font color="blue">scientists</font>, information technology specialists, financial and <font color="blue">legal specialists</font>,  <font color="blue">regulatory</font> professionals, quality compliance specialists and sales/marketing  personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Should <font color="blue">the Company </font></font>be unable to attract or retain key qualified  employees, future operating results may be <font color="blue"><font color="blue">adversely</font> impacted</font></td>
    </tr>
    <tr>
      <td>Conditions in Israel    <font color="blue">The Company </font>has <font color="blue">significant</font> <font color="blue">manufacturing</font> and research and <font color="blue">development</font>  <font color="blue">facilities</font> in Israel</td>
    </tr>
    <tr>
      <td>Political, economic and military <font color="blue">conditions</font> in Israel  <font color="blue">directly affect</font> the Companyapstas <font color="blue">operations</font> and <font color="blue">the Company </font>could be <font color="blue">adversely</font>  <font color="blue">affected by current</font> or <font color="blue">future <font color="blue">hostilities</font> involving</font> Israel or a <font color="blue">significant</font>  recession or downturn in the economic or <font color="blue">financial condition</font> of Israel</td>
    </tr>
    <tr>
      <td>Since the <font color="blue">establishment</font> of the State of Israel in 1948, a number of armed  conflicts have taken place between Israel and its <font color="blue">neighboring</font> countries</td>
    </tr>
    <tr>
      <td>A state  of hostility, varying in degree and intensity, has led to security and economic  problems for Israel</td>
    </tr>
    <tr>
      <td>The level of <font color="blue">hostilities</font> increased <font color="blue">significant</font>ly in July  2006 between <font color="blue">Israel and Hezbollah </font>in <font color="blue">neighboring</font> Lebanon</td>
    </tr>
    <tr>
      <td>As of the date of this  report, the hostile <font color="blue">operations</font> of these <font color="blue">groups continue</font> in Lebanon and northern  Israel and <font color="blue">hostilities</font> between <font color="blue">Israel and the Palestinians </font>have markedly  increased</td>
    </tr>
    <tr>
      <td>These <font color="blue">hostilities</font> have <font color="blue">adversely</font> affected Israelapstas <font color="blue"><font color="blue">relationship</font> with</font>  a number of countries in the region and elsewhere, as well as its <font color="blue">relationship</font>  with <font color="blue">international</font> <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>While none of the Companyapstas <font color="blue">facilities</font> in Israel have been <font color="blue">directly affect</font>ed by  the hostile <font color="blue">operations</font>, there can be no assurance that a <font color="blue">further escalation</font> of  <font color="blue">hostilities</font> will not impact the Companyapstas <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Furthermore, the Companyapstas  employees in Israel include members of the Israeli <font color="blue">military reserves</font>, some of  whom have <font color="blue">been <font color="blue">called up</font></font> for <font color="blue">active duty</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">significant</font> number of the  Companyapstas employees in Israel are <font color="blue">called up</font> for <font color="blue">active duty</font> in the military, the  Companyapstas <font color="blue">operations</font> in Israel may be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>-21-  <PAGE>    The <font color="blue">recent escalation</font> of <font color="blue">hostilities</font> has had a <font color="blue">disruptive</font> effect on Israelapstas  economy and any <font color="blue"><font color="blue">international</font> economic sanctions against</font> Israel <font color="blue">could further</font>  harm Israelapstas economy</td>
    </tr>
    <tr>
      <td>These economic <font color="blue">development</font>s could have an adverse effect  on the Companyapstas Israel Consumer Products and Israel Pharmaceutical and  <font color="blue">Diagnostic Products </font><font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">certain parties with whom</font> <font color="blue">the Company </font>does business may decline to  travel to Israel, <font color="blue">which would force</font> <font color="blue">the Company </font>to make <font color="blue">alternative</font> <font color="blue">arrangements</font>  where <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td><font color="blue">The United States Department of State </font>has issued an advisory  regarding travel to Israel</td>
    </tr>
    <tr>
      <td>As a result of the State Departmentapstas advisory, the  FDA has <font color="blue">at various times curtailed</font> or prohibited its inspectors from traveling  to Israel to inspect the <font color="blue">facilities</font> <font color="blue">of Israeli </font>companies, which, should it occur  <font color="blue">with respect</font> to the Company, could result in the FDA <font color="blue">withholding approval</font> for  <font color="blue">new products</font> intended to be produced at those <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Although it has not yet occurred, the political and security situation in Israel  may result in <font color="blue">certain parties with whom</font> <font color="blue">the Company </font>has contracts claiming that  they are not obligated to perform their <font color="blue">commitments pursuant</font> to <font color="blue">force majeure</font>  provisions of those contracts</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>could experience <font color="blue">disruption</font> of its <font color="blue">manufacturing</font> and research and  <font color="blue">development</font> <font color="blue">facilities</font> due to terrorist acts or <font color="blue">military actions</font></td>
    </tr>
    <tr>
      <td>If terrorist  acts or <font color="blue">military actions</font> were to result in substantial damage to the Companyapstas  <font color="blue">facilities</font>, business <font color="blue">activities</font> would be disrupted since, <font color="blue">with respect</font> to  <font color="blue">certain products</font>, <font color="blue">the Company </font>would need to obtain prior FDA approval for a  change in <font color="blue">manufacturing</font> site</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">insurance may</font> not <font color="blue">adequately</font>  compensate it for losses that may occur and any losses or <font color="blue">damages incurred by</font>  <font color="blue">the Company </font>could have a material adverse effect on its business</td>
    </tr>
    <tr>
      <td>Some <font color="blue">neighboring</font> countries, as well as certain companies and <font color="blue">organizations</font>,  continue to <font color="blue">participate</font> in a boycott <font color="blue">of Israeli </font>firms and others doing business  with Israel or with Israeli companies</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is <font color="blue">also precluded from</font>  marketing its products to certain of these <font color="blue">countries due</font> to <font color="blue">US and <font color="blue">Israeli  </font></font><font color="blue">regulatory</font> <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>Because none of the Companyapstas revenue is currently  <font color="blue">derived from sales</font> to these countries, <font color="blue">the Company </font>believes that the boycott has  not had a material adverse effect on its current <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>However,  continuation, extension of the boycott or <font color="blue">implementation</font> of <font color="blue">additional</font>  restrictive laws, policies or <font color="blue">practices directed towards</font> <font color="blue">Israel or <font color="blue">Israeli  </font></font><font color="blue">businesses</font> could have an <font color="blue">adverse <font color="blue">impact on</font></font> the expansion of the Companyapstas  business</td>
    </tr>
    <tr>
      <td>Healthcare and Legal Reforms    Increasing <font color="blue">expenditures</font> for healthcare have been the subject of considerable  <font color="blue">public attention</font> in Israel, North America and many European countries</td>
    </tr>
    <tr>
      <td>Both  private and <font color="blue"><font color="blue">governmental</font> entities</font> are <font color="blue">seeking ways</font> to reduce or contain  <font color="blue">healthcare costs</font></td>
    </tr>
    <tr>
      <td>In many countries in which <font color="blue">the Company </font>currently operates,  <font color="blue"><font color="blue">pharmaceutical</font> prices</font> are subject to regulation</td>
    </tr>
    <tr>
      <td>In the US, <font color="blue">numerous proposals</font>  that would effect changes in the US <font color="blue">healthcare system</font> and the <font color="blue">pharmaceutical</font>  industry have <font color="blue">been introduced</font> or proposed in <font color="blue">Congress </font>and in some state  <font color="blue">legislatures</font> that could include, but not be limited to, <font color="blue"><font color="blue">intellectual</font> property</font>,  <font color="blue">regulatory</font>, antitrust, drug pricing and <font color="blue">products <font color="blue">liability</font> issues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Similar  </font><font color="blue">activities</font> are taking place <font color="blue">throughout</font> Europe</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">governmental</font>  <font color="blue">budgetary</font> <font color="blue">constraints</font>, <font color="blue">the Israel Ministry of Health </font>and the major <font color="blue">Israeli  </font><font color="blue">health funds</font> have sought to further reduce <font color="blue">healthcare costs</font> by, among other  things, applying continuous pressure to reduce <font color="blue"><font color="blue">pharmaceutical</font> prices</font> and  <font color="blue">inventory levels</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict</font> the nature of the measures that may  be adopted, how they will be <font color="blue">interpreted by</font> the courts or the <font color="blue">administrative</font>  <font color="blue">agencies charged with enforcing them</font> or their <font color="blue">impact on</font> the marketing, pricing  and demand for its products</td>
    </tr>
    <tr>
      <td>-22-  <PAGE>    Pseudoephedrine - Retail Sales Controls    <font color="blue">The Company </font>continued to be <font color="blue">impacted by</font> the <font color="blue">legislative</font> and market changes  related to <font color="blue">products containing</font> <font color="blue">pseudoephedrine</font>, which have resulted from  <font color="blue">concerns over</font> the diversion and misuse of <font color="blue">pseudoephedrine</font> in the production of  <font color="blue">methamphetamine</font>, an <font color="blue">illegal drug</font></td>
    </tr>
    <tr>
      <td>Sales of these products in fiscal 2006 were  <font color="blue">approximately</font> dlra90cmam000 lower than year-to-date fiscal 2005</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>monitors  this <font color="blue">issue continuously</font> and, consequently, recorded an <font color="blue">additional</font> charge of  <font color="blue">approximately</font> dlra8cmam800 in fiscal 2006 for estimated <font color="blue">obsolete inventory on hand</font></td>
    </tr>
    <tr>
      <td>Based on recent events in the retail market, <font color="blue">legislative</font> actions and the  resulting lost sales, <font color="blue">management</font> believes that these issues <font color="blue">will continue</font> to  have a <font color="blue">significant</font> adverse effect on the Companyapstas results of <font color="blue">operations</font> in  fiscal 2007</td>
    </tr>
    <tr>
      <td>On March 10, 2006, <font color="blue">Congress </font>enacted the Patriot Act, which included the Combat  Methamphetamine Epidemic Act of 2005 (the Act)</td>
    </tr>
    <tr>
      <td>Among the various provisions,  this national <font color="blue">legislation</font> places certain <font color="blue">restrictions</font> on the purchase and sale  of all products that contain ephedrine, <font color="blue">pseudoephedrine</font>, or <font color="blue">phenylpropanolamine</font>  (<font color="blue">List I Chemical Products</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">Effective April </font>7, 2006, the Act <font color="blue">imposed quotas on</font>  <font color="blue">manufacture</font>rs and imposed daily <font color="blue">restrictions</font> on the amount of List I Chemical  Products a retailer may sell to a consumer (3dtta6 grams per day) and <font color="blue">limitations</font>  on the amount of <font color="blue">List I Chemical Products</font> a <font color="blue">consumer may purchase</font> (9dtta0 grams)  over a thirty-day period</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">effective</font> <font color="blue">September </font>30, 2006, the Act  requires that (a) <font color="blue">retail sellers</font> place all <font color="blue">List I Chemical Products</font> behind the  counter and maintain a logbook that tracks the sales of <font color="blue">List I Chemical Products</font>  to <font color="blue">individuals</font>, and (b) purchasers provide valid <font color="blue">identification</font> in order to  purchase <font color="blue">List I Chemical Products</font></td>
    </tr>
    <tr>
      <td>Many states have <font color="blue">also imposed statutory</font> and  <font color="blue">regulatory</font> <font color="blue">restrictions</font> on the <font color="blue">manufacture</font>, <font color="blue">distribution</font> and sale of  <font color="blue">pseudoephedrine</font> products</td>
    </tr>
    <tr>
      <td>For many of these products <font color="blue">impacted by</font> the above <font color="blue">legislation</font>, re<font color="blue">formulation</font> is  underway to substitute <font color="blue">pseudoephedrine</font> with <font color="blue">phenylephrine</font>, an ingredient that  cannot be used in the production of <font color="blue">methamphetamine</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has launched  <font color="blue">certain substitute products</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue"><font color="blue">phenylephrine</font> products</font> are in <font color="blue">various stages</font>  of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substitute </font><font color="blue">products will</font> become more <font color="blue">available over</font> time as new  national brand products are marketed and as <font color="blue">development</font> is completed</td>
    </tr>
    <tr>
      <td>Accordingly, these <font color="blue">products will</font> be phased in for sales to <font color="blue">customers over</font> the  <font color="blue">next several fiscal quarters</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict</font> if all  <font color="blue">pseudoephedrine</font>-containing products can be <font color="blue">successfully</font> reformulated with  <font color="blue">phenylephrine</font> or if consumers will accept <font color="blue">phenylephrine</font> as an adequate  substitute for <font color="blue">pseudoephedrine</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dextromethorphan </font>   <font color="blue">The Company </font><font color="blue">manufacture</font>s several products that contain the active ingredient  <font color="blue">dextromethorphan</font>, which is indicated for <font color="blue">cough suppression</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dextromethorphan </font>has  <font color="blue">come under scrutiny</font> because of its potential to be abused</td>
    </tr>
    <tr>
      <td>Some states have  introduced <font color="blue">legislation</font> that, if passed, could require <font color="blue">restricted access</font> to  <font color="blue">dextromethorphan</font> in finished <font color="blue">dosage forms</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">at least one</font> state has  passed <font color="blue">legislation</font> restricting the bulk sale of <font color="blue">dextromethorphan</font>, no state  <font color="blue">legislation</font> has <font color="blue">yet been enacted restricting</font> the sale of <font color="blue">dextromethorphan</font> in  finished dosages and <font color="blue">concentrations</font> for use as an OTC drug</td>
    </tr>
    <tr>
      <td>Similarly, on the  federal level, <font color="blue">legislation</font> has <font color="blue">been introduced</font> (the <font color="blue">Dextromethorphan </font> Distribution Act of 2006) which, if passed, would allow the FDA to promulgate  <font color="blue">regulations</font> on the sale of unfinished <font color="blue">dextromethorphan</font> and limit the  <font color="blue">distribution</font> of the bulk ingredient only to those persons or <font color="blue">entities which</font> are  <font color="blue">registered with</font> the FDA Due to the <font color="blue">recent scrutiny</font> of <font color="blue">dextromethorphan</font>, it is  possible that any of the states or the <font color="blue">federal government could introduce</font> and  pass <font color="blue">legislation</font> imposing <font color="blue">restrictions</font> on the sale of <font color="blue">dextromethorphan</font> in  finished dosage form, including but not limited to requiring a <font color="blue">minimum age</font> to  purchase product, limiting the amount a <font color="blue">consumer may purchase</font>, requiring a  <font color="blue">prescription</font> and/or placing the product in a more <font color="blue">controlled position</font> of sale  behind the <font color="blue">pharmacy counter</font> of a retailer</td>
    </tr>
    <tr>
      <td>Products containing <font color="blue">dextromethorphan</font>  generated <font color="blue">approximately</font> dlra76cmam000 of the Companyapstas revenues in fiscal 2006</td>
    </tr>
    <tr>
      <td>The  Company <font color="blue">cannot predict</font> whether any of the proposed <font color="blue">legislation</font> will be passed,  or if it is passed, its <font color="blue">impact on</font> future revenues attributable to these  products</td>
    </tr>
    <tr>
      <td>-23-  <PAGE>    Product Issues - Effect of Misuse and Publicity    The Companyapstas products are safe and <font color="blue">effective</font> when used in <font color="blue">accordance with</font> label  <font color="blue">directions</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">certain products</font> contain <font color="blue">ingredients</font> that can be, and in  some cases are, used for <font color="blue">improper purposes</font></td>
    </tr>
    <tr>
      <td>As <font color="blue">previously discussed</font>,  <font color="blue">pseudoephedrine</font> and <font color="blue">dextromethorphan</font> are two of these <font color="blue">ingredients</font>, but others  may exist</td>
    </tr>
    <tr>
      <td>Increasingly, <font color="blue">various efforts</font> are <font color="blue">employed by federal</font> and state  <font color="blue">governments</font> in an effort to curb this misuse, including the <font color="blue">consideration</font> of  <font color="blue">additional</font> <font color="blue">legislation</font> or regulation that may result in <font color="blue">further restrictive</font>  <font color="blue">requirements</font> for the <font color="blue">manufacture</font> or sale of <font color="blue">products containing</font> these  <font color="blue">ingredients</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict</font> if or when any <font color="blue">additional</font> <font color="blue">legislation</font> or  <font color="blue">regulation will</font> be approved</td>
    </tr>
    <tr>
      <td>If this type of <font color="blue">additional</font> <font color="blue">legislation</font> or  regulation is approved, it could have an <font color="blue">adverse <font color="blue">impact on</font></font> the Companyapstas results  of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A broad class of pain relievers known as non-steroidal anti-inflammatory drugs  (NSAID), such as ibuprofen, naproxen and others, has <font color="blue">come under scrutiny</font> by the  <font color="blue">FDA The FDA </font>has requested <font color="blue">manufacture</font>rs of NSAID <font color="blue">provide labeling which</font>  contains a warning that the long-term, continuous use of these <font color="blue">products may</font>  increase a consumerapstas cardiovascular risk</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has <font color="blue">complied with</font> the  request, but <font color="blue">cannot predict</font> if this warning will <font color="blue">adversely</font> impact the future  sales of these products or the Companyapstas results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>believes that growth in the <font color="blue">nutritional products</font> business is based  <font color="blue">largely on national <font color="blue">media attention</font></font> regarding <font color="blue">scientific research</font> suggesting  <font color="blue">potential health benefits from regular consumption</font> of <font color="blue">certain vitamin</font> and other  <font color="blue">nutritional products</font></td>
    </tr>
    <tr>
      <td>There can be no assurance of future favorable scientific  results and <font color="blue">media attention</font>, or the absence of unfavorable or <font color="blue">inconsistent</font>  findings</td>
    </tr>
    <tr>
      <td>In the event of future unfavorable scientific results or media  attention, the Companyapstas sales of <font color="blue">nutritional products</font> could be <font color="blue">materially</font>  <font color="blue"><font color="blue">adversely</font> impacted</font></td>
    </tr>
    <tr>
      <td>Patent and Trade Dress Issues    The Companyapstas ability to bring <font color="blue">new products</font> to market is limited by certain  patent and <font color="blue">trade dress factors</font> including, but not limited to, the existence of  <font color="blue">patents protecting</font> brand products for the Consumer Healthcare, API and Rx  Pharmaceuticals segments and the <font color="blue">regulatory</font> <font color="blue">exclusivity</font> periods awarded on  products that have <font color="blue">switched from <font color="blue">prescription</font></font> to OTC status</td>
    </tr>
    <tr>
      <td>The cost and time  to develop these <font color="blue">prescription</font> and <font color="blue">switch products</font> is <font color="blue">significant</font>ly greater than  the rest of the <font color="blue">new products</font> that <font color="blue">the Company </font>seeks to introduce</td>
    </tr>
    <tr>
      <td>Moreover, the  <font color="blue">manufacture</font>, use and sale of <font color="blue">new products</font> that are the subject of <font color="blue">conflicting</font>  patent rights have been the subject of substantial <font color="blue">litigation</font> in the  <font color="blue">pharmaceutical</font> industry</td>
    </tr>
    <tr>
      <td>These lawsuits relate to the validity and <font color="blue">infringement</font>  of patents or <font color="blue">proprietary rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may have to  <font color="blue">defend against charges</font> that it <font color="blue">violated patents</font> or <font color="blue">proprietary rights</font> of third  parties</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">defense against charges</font> that it infringed <font color="blue">third party</font>  patents or <font color="blue">proprietary rights</font> could require <font color="blue">the Company </font>to incur substantial  expense and to divert <font color="blue">significant</font> effort of its technical and <font color="blue">management</font>  personnel</td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Company </font></font><font color="blue">infringes on</font> the rights of others, it could lose its  right to develop or <font color="blue">manufacture</font> some products or could be required to pay  <font color="blue">monetary damages</font> or royalties to license <font color="blue">proprietary rights</font> from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Although the parties to patent and <font color="blue"><font color="blue">intellectual</font> property</font> disputes in the  <font color="blue">pharmaceutical</font> industry have <font color="blue">often settled</font> their <font color="blue">disputes through licensing</font> or  similar <font color="blue">arrangements</font>, the <font color="blue">costs associated with</font> these <font color="blue">arrangements</font> may be  substantial and could include <font color="blue">ongoing royalties</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">the Company </font>cannot  be certain that the <font color="blue">necessary</font> licenses would be available to it on terms it  believes to be acceptable</td>
    </tr>
    <tr>
      <td>As a result, an adverse <font color="blue">determination</font> in a judicial  or <font color="blue">administrative</font> proceeding or failure to obtain <font color="blue">necessary</font> licenses could  prevent <font color="blue">the Company </font>from <font color="blue">manufacturing</font> and selling a number of its products</td>
    </tr>
    <tr>
      <td>At times, <font color="blue">the Company </font><font color="blue">may seek approval</font> to market generic <font color="blue"><font color="blue">prescription</font> products</font>  before the expiration of patents for those products, based upon its belief that  <font color="blue">such patents</font> are invalid, unenforceable or would not be <font color="blue">infringed by</font> its                                          -24-  <PAGE>    products</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">the Company </font>may face <font color="blue">significant</font> patent <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon a <font color="blue">complex analysis</font> of a variety of legal and <font color="blue">commercial factors</font>,  <font color="blue">the Company </font>may, in <font color="blue">certain <font color="blue">circumstances</font></font>, elect to market a generic  <font color="blue">prescription</font> product while <font color="blue">litigation</font> is pending, before any <font color="blue">court decision</font> or  while an appeal of a lower <font color="blue">court decision</font> is pending</td>
    </tr>
    <tr>
      <td><font color="blue">Should <font color="blue">the Company </font></font>elect  to proceed in this manner, <font color="blue">the Company </font>could face substantial <font color="blue">patent <font color="blue">liability</font></font>  damages if the final <font color="blue">court decision</font> is adverse to it</td>
    </tr>
    <tr>
      <td>Protection of Intellectual Property Rights    The Companyapstas <font color="blue">success with certain</font> of its <font color="blue">products depends</font>, in part, on its  ability to protect its current and <font color="blue">future products</font> and to defend its  <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Company </font></font>fails to <font color="blue">adequately</font> protect its  <font color="blue"><font color="blue">intellectual</font> property</font>, <font color="blue">competitors</font> may <font color="blue">manufacture</font> and market similar products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has been issued patents covering certain of its products, and has  filed, and expects to continue to file, patent applications seeking to protect  newly developed <font color="blue">technologies</font> and products in <font color="blue">various countries</font>, including the  US Any existing or future patents issued to or licensed by <font color="blue">the Company </font>may not  provide it with any <font color="blue">significant</font> <font color="blue">competitive</font> advantages for its products or may  even be challenged, invalidated or circumvented by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In addition,  such patent rights may not prevent the Companyapstas <font color="blue">competitors</font> from developing,  using or commercializing non-infringing products that are similar or  functionally equivalent to its products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also relies on trade secrets, unpatented proprietary know-how and  <font color="blue">continuing technological innovation</font> that it seeks to protect, in part by  <font color="blue">confidentiality agreements</font> with licensees, suppliers, employees and consultants</td>
    </tr>
    <tr>
      <td>Disputes may arise concerning the ownership of <font color="blue">intellectual</font>  property or the <font color="blue">applicability</font> of <font color="blue">confidentiality agreements</font></td>
    </tr>
    <tr>
      <td>Furthermore, trade  secrets and <font color="blue">proprietary technology may otherwise become known</font> or be  <font color="blue">independently</font> developed by <font color="blue">competitors</font> or, if patents are not <font color="blue">issued with</font>  respect to products arising from research, <font color="blue">the Company </font>may not be able to  maintain the value of such <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>Legal Exposure    From time to time, <font color="blue">the Company </font>and/or its <font color="blue"><font color="blue">subsidiaries</font> become involved</font> in  lawsuits arising <font color="blue">from various commercial matters</font>, including, but not limited to,  <font color="blue">competitive</font> issues, contract issues, <font color="blue"><font color="blue">intellectual</font> property</font> matters, workers &amp;apos   compensation, product <font color="blue">liability</font> and state or federal <font color="blue">regulatory</font> issues</td>
    </tr>
    <tr>
      <td><font color="blue">See Item  </font>3</td>
    </tr>
    <tr>
      <td><font color="blue">Legal Proceedings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>tends to be unpredictable and costly</td>
    </tr>
    <tr>
      <td>No  assurance can be made that <font color="blue">litigation</font> will not have a material adverse effect on  the Companyapstas <font color="blue">financial position</font> or results of <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">judicial decisions</font> in <font color="blue">proceedings</font> to which <font color="blue">the Company </font>is not a party  may result in the setting of <font color="blue">legal precedent</font> that <font color="blue">could affect</font> the future  operation of the Companyapstas business</td>
    </tr>
    <tr>
      <td>-25-  <PAGE>    Availability of Raw Materials and Supplies    High <font color="blue">quality <font color="blue">raw materials</font></font> and <font color="blue">packaging components</font> are essential to all of the  Companyapstas business units due to the nature of the products it <font color="blue">manufacture</font>s</td>
    </tr>
    <tr>
      <td>Raw  materials and <font color="blue">packaging components</font> are generally available from multiple  suppliers</td>
    </tr>
    <tr>
      <td>Supplies of certain <font color="blue">raw materials</font>, bulk tablets and finished goods  purchased by <font color="blue">the Company </font>are limited, or are <font color="blue">available from one</font> or only a few  suppliers</td>
    </tr>
    <tr>
      <td>In response to these problems <font color="blue">the Company </font>tries to identify <font color="blue">alternative</font>  materials or suppliers for such <font color="blue">raw materials</font>, bulk tablets and finished goods</td>
    </tr>
    <tr>
      <td>Certain material shortages and approval of <font color="blue">alternate sources</font>  could <font color="blue">adversely</font> affect financial results</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>continues to increase its <font color="blue">revenues outside</font> the  US The Companyapstas <font color="blue">primary markets</font> for the sale of its products outside the US  are Canada, Germany, Israel, Mexico and the UK <font color="blue">The Company </font>may have difficulty  in <font color="blue">international</font> markets due, for example, to <font color="blue">regulatory</font> barriers, the <font color="blue">necessity</font>  of adapting to new <font color="blue">regulatory</font> systems and problems related to <font color="blue">markets with</font>  <font color="blue">different cultural bases</font> and <font color="blue">political systems</font></td>
    </tr>
    <tr>
      <td>Sales to customers outside the  US and foreign raw material purchases expose <font color="blue">the Company </font>to a number of risks  including unexpected changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>, possible <font color="blue">difficulties</font>  in enforcing agreements, longer payment cycles, longer shipping lead-times,  inefficient port <font color="blue">operations</font>, exchange rate <font color="blue">fluctuation</font>s, <font color="blue">difficulties</font> obtaining  export or <font color="blue">import licenses</font>, the imposition of withholding or other taxes,  economic or political instability, embargoes, military <font color="blue">hostilities</font> or exchange  controls</td>
    </tr>
    <tr>
      <td>Should any of these risks occur, they may have a material adverse  <font color="blue">impact on</font> the operating results of the Company</td>
    </tr>
    <tr>
      <td>Customs and Trade Regulation    <font color="blue">The Company </font>imports and <font color="blue">exports products</font> and <font color="blue"><font color="blue">raw materials</font> from several</font>  <font color="blue">jurisdictions around</font> the world</td>
    </tr>
    <tr>
      <td>This <font color="blue">process involves</font> Company <font color="blue">subsidiaries</font> and  <font color="blue">third parties</font> operating in a number of <font color="blue">jurisdictions with different customs</font> and  import/export <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulations</font> are subject to change from time to  time and <font color="blue">the Company </font><font color="blue">cannot predict</font> the nature, scope or <font color="blue">impact upon</font> the  Companyapstas <font color="blue">operations</font> of these changes</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to periodic  reviews and <font color="blue">audits by</font> US and foreign <font color="blue">authorities</font> responsible for <font color="blue">administering</font>  these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue">the Company </font>is unable to <font color="blue">successfully</font>  <font color="blue">defend itself against</font> an audit or review, <font color="blue">the Company </font>may be required to pay  <font color="blue">assessments</font> and penalties and increased duties, which may, individually or in  the aggregate, negatively impact the Companyapstas gross margins and operating  results</td>
    </tr>
    <tr>
      <td>Certain of the Companyapstas <font color="blue">facilities</font> operate in a special purpose  subzone established by the US Department of Commerce Foreign Trade Zone Board,  which allows <font color="blue">the Company </font><font color="blue">certain tax advantages on products</font> and <font color="blue">raw materials</font>  shipped through these <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Entry into new tax jurisdictions, whether domestic or <font color="blue">international</font>,  increases the likelihood of <font color="blue">fluctuation</font></td>
    </tr>
    <tr>
      <td>To continue to  be eligible for these grants, the Companyapstas <font color="blue">development</font> projects must be  <font color="blue">approved by</font> the <font color="blue">Chief Scientist </font>on a case-by-case basis</td>
    </tr>
    <tr>
      <td>If the Companyapstas  <font color="blue">development</font> projects are not <font color="blue">approved by</font> the Chief Scientist, <font color="blue">the Company </font>will  not receive grants to fund these projects, <font color="blue">which would increase research</font> and  <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td>The receipt of <font color="blue">such grants subjects</font> <font color="blue">the Company </font>to certain  <font color="blue">restrictions</font> and pre-approval <font color="blue">requirements</font> which may be <font color="blue">conditioned</font> by  <font color="blue">additional</font> royalty payments with rights to transfer of <font color="blue"><font color="blue">intellectual</font> property</font>  and/or production abroad</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also receives <font color="blue">tax benefits</font>, in particular  <font color="blue">exemptions</font> and <font color="blue">reductions as</font> a result of the <font color="blue">approved enterprise status</font> of  certain existing <font color="blue">operations</font> in Israel</td>
    </tr>
    <tr>
      <td>To be eligible for these <font color="blue">tax benefits</font>,  <font color="blue">the Company </font>must maintain its <font color="blue">approved enterprise status</font> by meeting <font color="blue">conditions</font>,  including making specified <font color="blue"><font color="blue">investment</font>s</font> in fixed <font color="blue">assets located</font> in Israel and  investing <font color="blue">additional</font> equity in itself and its Israeli <font color="blue">subsidiaries</font> and by  <font color="blue">meeting projections provided</font> to the <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Company </font></font>fails to  meet these <font color="blue">conditions</font> in the future, the <font color="blue">tax benefits</font> would be canceled and the  Company could be required to refund the <font color="blue">tax benefits</font> already received</td>
    </tr>
    <tr>
      <td>These tax  benefits may not be continued in the future at their <font color="blue">current levels</font> or at any  level</td>
    </tr>
    <tr>
      <td>If <font color="blue">such benefits</font> are reduced or eliminated in the future, the Companyapstas  results of <font color="blue">operations</font> will be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>Goodwill and Other Intangibles    <font color="blue">The Company </font><font color="blue">tests goodwill</font> for <font color="blue">impairment</font> annually or more <font color="blue">frequently</font> if changes  in <font color="blue">circumstances</font> or the occurrence of events suggest <font color="blue">impairment</font> exists</td>
    </tr>
    <tr>
      <td>The test  for <font color="blue">impairment</font> requires <font color="blue">the Company </font>to make several estimates about <font color="blue">fair value</font>,  most of which are based on projected <font color="blue">future cash</font> flows</td>
    </tr>
    <tr>
      <td>Changes in these  estimates may result in the <font color="blue">recognition</font> of an <font color="blue">impairment</font> loss</td>
    </tr>
    <tr>
      <td>The Companyapstas  testing in the 2006 fiscal year resulted in no <font color="blue">impairment</font> charges related to  goodwill</td>
    </tr>
    <tr>
      <td>The testing performed on the Companyapstas UK component within the  <font color="blue">Consumer Healthcare </font>segment, however, indicated that while the estimated fair  value exceeded the carrying value, these values were <font color="blue">closer than</font> they had been  in <font color="blue">previous years</font></td>
    </tr>
    <tr>
      <td>The narrowing of the difference in these <font color="blue">values increases</font> the  <font color="blue">possibility</font> that unfavorable changes in the <font color="blue">future financial</font> results of this  business could result in an <font color="blue">impairment</font> charge in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">intangible assets</font> subject to <font color="blue"><font color="blue">amortization</font> consist</font> of developed product  technology, <font color="blue">distribution</font> and license agreements, customer <font color="blue">relationship</font>s and  <font color="blue">trademarks</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">intangible assets</font> subject to <font color="blue">amortization</font>, an <font color="blue">impairment</font>  analysis is performed <font color="blue">whenever events</font> or changes in <font color="blue">circumstances</font> indicate that  the carrying amount of the <font color="blue">assets may</font> not be recoverable</td>
    </tr>
    <tr>
      <td>An <font color="blue">impairment</font> loss is  recognized if the carrying amount of the asset is not recoverable and its  carrying <font color="blue">amount exceeds</font> its <font color="blue">fair value</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> change in market  <font color="blue">conditions</font> and estimates or <font color="blue">judgments used</font> to determine expected <font color="blue">future cash</font>  flows that indicate a reduction in carrying <font color="blue">value may give rise</font> to <font color="blue">impairment</font> in  the period that the change <font color="blue">becomes known</font></td>
    </tr>
    <tr>
      <td>Insurance Costs    <font color="blue">The Company </font>maintains insurance, including property, general and product  <font color="blue">liability</font>, and directors &amp;apos  and officers &amp;apos  <font color="blue">liability</font>, to <font color="blue">protect itself against</font>  <font color="blue">potential loss exposures</font></td>
    </tr>
    <tr>
      <td>To the extent that losses occur, there could be an  adverse effect on the Companyapstas financial results <font color="blue">depending on</font> the nature of the  loss and the level of <font color="blue">insurance coverage</font> maintained by the Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font> <font color="blue">cannot predict</font> whether deductible or <font color="blue">retention amounts will increase</font> or whether  <font color="blue">coverage will</font> be reduced in the future</td>
    </tr>
    <tr>
      <td>From time to time, <font color="blue">the Company </font>may  reevaluate and change the types and levels of <font color="blue">insurance coverage</font> that it  purchases</td>
    </tr>
    <tr>
      <td>-27-  <PAGE>    Exposure to Product Liability Claims    The Company, like other retailers, distributors and <font color="blue">manufacture</font>rs of products  that are ingested, is exposed to product <font color="blue">liability</font> claims in the event that,  among other things, the use of its products results in injury</td>
    </tr>
    <tr>
      <td>There is no  assurance that product <font color="blue">liability</font> insurance <font color="blue">will continue</font> to be available to the  Company at an <font color="blue">economically reasonable cost</font> (or at all for <font color="blue">certain products</font>) or  that the Companyapstas <font color="blue">insurance will</font> be adequate to cover <font color="blue">liability</font> that the</td>
    </tr>
  </tbody>
</table>